The olive tree has inspired beauty for 4,000 years and now it walks the runway at New York Fashion Week

Olive_Tree_People_F97

F97 Deep Glow Hydrogel Face Mask: A waterless hydrogel mask built on olive fruit juice instead of water, with sodium hyaluronate for lasting moisture. As the essence absorbs, the mask gradually turns transparent — and skin is left feeling smoother, softer, and refreshed.
F97 Deep Glow Hydrogel Face Mask: A waterless hydrogel mask built on olive fruit juice instead of water, with sodium hyaluronate for lasting moisture. As the essence absorbs, the mask gradually turns transparent — and skin is left feeling smoother, softer, and refreshed.

Olive_Tree_People_F96

F96 Olive Glow Eye Patches | Waterless hydrogel eye patches that combine olive fruit juice, naturally rich in antioxidants, with sodium hyaluronate for lasting hydration — leaving the delicate eye area feeling smoother, softer, and revitalized.
F96 Olive Glow Eye Patches | Waterless hydrogel eye patches that combine olive fruit juice, naturally rich in antioxidants, with sodium hyaluronate for lasting hydration — leaving the delicate eye area feeling smoother, softer, and revitalized.

SANTA MONICA, CA, Sept. 11, 2026 (GLOBE NEWSWIRE) — Oliveda International, Inc. (OTCID: OLVI) today announced that its OLIVE TREE PEOPLE subsidiary and the Olive Rose makeup brand are joining forces with internationally acclaimed fashion designer Bibhu Mohapatra for his New York Fashion Week show in the Grand Ballroom of The Pierre Hotel in Manhattan.

For more than 4,000 years, the olive tree has been one of humanity’s most enduring symbols of beauty, vitality and transformation.

This Monday, it becomes couture.

Bibhu Mohapatra is transforming the world of Olive Tree People and Olive Rose into an exclusive couture creation – while than 20 makeup artists and an unprecedented front-row beauty ritual take over New York Fashion Week.

At the heart of the collaboration will be the unveiling of a one-of-one Olive Rose gown, created by Mohapatra exclusively for Olive Tree People, Oliveda and Olive Rose.

The design brings together two worlds: the olive tree, represented through its iconic leaves, and Olive Rose, expressed through the beauty and sensuality of the rose.

It is not simply a dress featuring the symbols of two brands.

It is the story of an ancient tree transformed into modern couture.

The olive tree becomes fashion.
The rose becomes movement.
And a 4,000-year-old beauty secret walks the runway.

“For thousands of years, the olive tree has represented beauty, strength and life. Bibhu did not simply place olive leaves and roses on a dress. He translated the soul of our world into couture. On Monday, the olive tree will no longer stand beside the runway. It will walk it,” said Thomas Lommel, Founder of Olive Tree People.

MORE THAN A BEAUTY PARTNERSHIP

Behind the scenes, Olive Tree People and Olive Rose will lead the beauty experience for the show.

A team of more than 20 makeup artists, under the direction of Olive Rose Chief Celebrity Makeup Artist Luis Casco, will create the runway beauty looks and prepare the models and invited VIP guests.

Olive Rose first appeared at New York Fashion Week last year, where it was celebrated as the world’s only makeup line based on Hydroxytyrosol.

This year, Olive Rose returns on an entirely new scale – not only on the faces of the models, but as the inspiration for an exclusive Bibhu Mohapatra couture creation and an unforgettable beauty experience extending from backstage to the front row.

THE FRONT ROW WILL BECOME PART OF THE SHOW

In keeping with an Olive Tree People tradition, guests will be offered individually hand-braided olive crowns—an ancient symbol of beauty, peace, strength and victory.

But this year, the tradition will be taken one step further.

To celebrate the launch of the new Olive Tree People Hydroxytyrosol Hydrogel Face Masks and Eye Patches, front-row guests will be invited to participate in a choreographed beauty ritual before the runway show begins.

Wearing the new Hydroxytyrosol treatments together with their olive crowns, the most photographed guests in the room will create one of New York Fashion Week’s most unexpected images:

An entire front row crowned by the olive tree—with their faces beneath Hydroxytyrosol masks.

For a few extraordinary minutes, the front row will stop observing beauty and begin experiencing it.

No hiding the treatment behind a bathroom door.
No pretending beauty happens effortlessly.
No waiting until Fashion Week is over to take care of the skin.

Instead, skincare will take the best seat in fashion.

FROM BACKSTAGE TO THE RUNWAY—AND ONTO THE SKIN

The collaboration connects every part of the Olive Tree People universe.

The olive tree inspires the dress.
Olive Rose creates the color.
Hydroxytyrosol touches the skin.
The olive crowns transform the guests.
And Bibhu Mohapatra brings the entire story to life through fashion.

It is a meeting of ancient beauty intelligence and modern creative expression—inside one of Manhattan’s most iconic ballrooms.

One ancient tree.
One exclusive couture creation.
More than 20 makeup artists.
And a front row New York Fashion Week will not forget.

ABOUT OLIVE TREE PEOPLE
Olive Tree People is a pioneer and leading force in waterless beauty. Instead of using the conventional water phase found in most skincare products, the company replaces water with its proprietary olive leaf cell elixir and combines it with powerful olive-tree ingredients, including Hydroxytyrosol.

Founded by olive tree farmer Thomas Lommel, Olive Tree People develops skincare, beauty and holistic experiences based on more than 20 years of work with mountain olive trees and the principles of Olive Tree Therapy.

ABOUT OLIVE ROSE
Olive Rose is the color cosmetics world of Olive Tree People and Oliveda. Introduced at New York Fashion Week as the world’s only makeup line based on Hydroxytyrosol, Olive Rose brings together high-performance color, skincare intelligence and the transformative beauty of the olive tree.

About Oliveda International, Inc. 
Oliveda International, Inc. and its subsidiary, Olive Tree People Inc., as well as the European companies, Olive Tree People Europe AG, Oliveda Deutschland GmbH, and Olive Tree Farmers SL, were founded by the German real estate investor Thomas Lommel. The companies possess over 20 years of experience in management and organic certification growing mountain olive trees; in the extraction of first-class, internationally award-winning extra virgin olive oils; the extraction of hydroxytyrosol; and the production and distribution of cosmetic and holistic waterless products related to the olive tree.  Lommel is the inventor of the “Olive Tree Therapy 10 Years in 14 Days” as well as the inventor of olive matcha, which is based on the ground olive leaf. Also unique is the coffee replacement developed by Lommel, which is based on the olive leaf and hydroxytyrosol.  In addition, Lommel is successfully active in the rapidly growing mindfulness industry with the olive tree sound bath meditation he developed and the frequencies of his olive trees, which he makes available worldwide.

In addition to the registered beauty brands, Oliveda and LA Dope, as well as the brands Olive Rose, OLIVE re:connected to Nature, The Intuition of Nature, Olive Mush, Baby & Mom, and Is That Matty?, Lommel is the region’s largest conservationist and protector of over 30,000 one-hundred-year-old mountain olive trees. With his Thomas Lommel Foundation, he brings the water that he does not use into his waterless beauty products to the people of Africa by building water wells on site.

The company’s direct-to-consumer network includes tens of thousands of Waterless Beauty Consultants in North America and Europe. In addition to online sales and a Europe-wide branch network of thousands of retail stores, Oliveda Deutschland GmbH operates its own flagship stores in Berlin and Düsseldorf.

The brand’s treatment concepts are unique worldwide, and their effectiveness has been confirmed by conventional medicine.  Read our book The Olive Tree Therapy 10 Years in 14 Days. Waterless beauty has been called “The Next Big Thing” in articles in U.S. Vogue, Harper’s Bazaar, InStyle, Elle, Madame, Forbes, and many other industry publications, as well as by Mintel, a world-leading futurology institute.  Gigi Hadid and many other celebrities are already Oliveda fans and support its success.  Further information on Oliveda International, Inc. and its subsidiaries and associate companies and brands can be found at www.olivetreepeople.com

Forward-Looking Statements
This press release may contain statements, estimates or projections that constitute “forward-looking statements” pursuant to the safe harbor provisions of the U.S. federal securities laws. Generally, the words “believe,” “expect,” “intend,” “estimate,” “anticipate,” “project,” “will” and similar expressions identify forward-looking statements, which generally are not historical in nature. Forward-looking statements are subject to certain risks and uncertainties, which may be found in the Company’s filings with OTC Markets Group Inc., that could cause actual results to differ materially from the Company’s historical experience and present expectations or projections. Investors should not place undue reliance on forward-looking statements, which speak only as of the date they are made.  The Company expressly disclaims any obligation or intention to publicly update or revise any forward-looking statements unless otherwise required by law.

Attachments

CONTACT: OLVI Investor Relations
619-202-7456
olvi@advanceprgroup.com

ProVen VCT plc 
Issue of Equity
11 September 2026

The Directors of ProVen VCT plc announce an allotment on 11 September 2026 of ordinary shares of 10p each (“Ordinary Shares”) pursuant to the offer for subscription that opened on 17 November 2025. The allotment also included a small number of shares issued to existing shareholders in satisfaction of commission payments due to their brokers.

1,141,293 Ordinary Shares were allotted at an average price of 61.41p, based on the latest net asset value of 59.5p, being the net asset value per Ordinary Share as at 31 May 2026 adjusted for the dividend of 1.6p paid on 14 August 2026. 7,243 Ordinary Shares were allotted at the same price in connection with commission payments. The total Ordinary Shares allotted were 1,148,536.

Application for the shares to be admitted to the Official List of the Financial Conduct Authority and to trading on the London Stock Exchange’s market for listed securities will be made shortly.

These shares will rank pari passu with existing Ordinary Shares.

Following this allotment, the issued share capital and total voting rights of ProVen VCT plc is 298,575,634 Ordinary Shares.

Beringea LLP
Company Secretary
Telephone 020 7845 7820

-End-

ProVen Growth and Income VCT plc
Issue of Equity
11 September 2026

The Directors of ProVen Growth and Income VCT plc announce an allotment on 11 September 2026 of ordinary shares of 1.6187p each (“Ordinary Shares”) pursuant to the offer for subscription that opened on 17 November 2025. The allotment also included a small number of shares issued to existing shareholders in satisfaction of commission payments due to their brokers.

709,540 Ordinary Shares were allotted at an average price of 48.09p, based on the latest net asset value of 46.3p, being the net asset value per Ordinary Share as at 31 May 2026 adjusted for the dividend of 1.3p paid on 14 August 2026. 3,463 Ordinary Shares were allotted at the same price in connection with commission payments. The total Ordinary Shares allotted were 713,003.

Application for the shares to be admitted to the Official List of the Financial Conduct Authority and to trading on the London Stock Exchange’s market for listed securities will be made shortly.

These shares will rank pari passu with existing Ordinary Shares.

Following this allotment, the issued share capital and total voting rights of the ProVen Growth and Income VCT plc is 328,019,357 Ordinary Shares.

Beringea LLP
Company Secretary
Telephone 020 7845 7820

-End-

Reference is made to the stock exchange notice sent Thursday 10 September 2026.
SalMar ASA (rated BBB by Nordic Credit Rating) has today, 11 September 2026, completed an extension of NOK 250 million on its commercial paper NO0013770180, coupon 5,37% p.a., settlement date 15 September 2026 and maturity date 15 September 2027. Following the extension, the total outstanding volume of the commercial paper will amount to NOK 500 million.

Manager: DNB Carnegie

This information is subject to the disclosure requirements stipulated in section 5-12 of the Norwegian Securities Trading Act.

FORESIGHT ENTERPRISE VCT PLC
LEI: 213800MWJNR3WZZ3ZP42

INTENTION TO FUNDRAISE
11 SEPTEMBER 2026

The Board of Foresight Enterprise VCT plc is pleased to announce that the Company intends to open an offer for subscription of new ordinary shares of up to £20 million later this year (the ‘Offer’). An Offer document will be available in due course.

For further information, please contact:

Company Secretary:
Foresight Group LLP
Contact: Stephen Thayer Tel: 0203 667 8100

Investor Relations:
Foresight Group LLP
Contact: Andrew James Tel: 0203 667 8181

The Appointments Add Experience Across Technology, Food and Beverage, Franchising, Branding, and Logistics

BREA, Calif., Sept. 11, 2026 (GLOBE NEWSWIRE) — Reborn Coffee Inc. (Nasdaq: REBN) (the “Company”), a leader in the specialty coffee market, today announced the appointment of Edward Park and James Lim to its Board of Directors (the “Board”), effective September 3, 2026.

Mr. Park and Mr. Lim were appointed to fill vacancies on the Board following the Board’s decision to increase its authorized size from seven to eight members. Each director will serve until the Company’s next annual meeting of stockholders or until his successor is duly appointed and qualified, subject to earlier death, resignation, retirement, disqualification, removal from office or other cause.

The appointments broaden the range of operating and industry experience represented on the Board. Mr. Park brings more than 26 years of experience spanning advanced technology and international business management. His background includes senior and leadership roles in the computer and networking industries, including point-of-sale systems, fiber-optic communications, and high-speed networking. Mr. Park also has experience assisting with the development and management of franchise and restaurant businesses. He has served as chief executive officer of multiple companies. Earlier in his career, he held senior positions with Samsung Electronics Co. Ltd, Novell Korea, and Harmonic Inc. Mr. Park holds a Master of Electrical Engineering degree from Seoul National University and has received notable recognition for technology and sales performance during his career.

Mr. Lim brings more than 15 years of experience in coffee distribution, roasting, and branding. After graduating from Kookmin University with a degree in Education, he began his career in the coffee industry with a coffee distribution and roasting company. He subsequently spent more than ten years at Hollys Coffee in Seoul, South Korea, where his responsibilities included coffee distribution, roasting, and branding, followed by approximately five years at Caffe Bene where he served as General Manager. Mr. Lim currently works in the logistics industry in the United States.

Together, the appointments add perspectives spanning brand development, franchise operations, logistics, technology, and international business management. The Company believes this combination of experience will provide additional depth to the Board as it oversees Reborn Coffee’s operations and long-term business priorities.

Neither Mr. Park nor Mr. Lim has been appointed to a committee of the Board at this time, and neither will receive compensation for service as a director.

About Reborn Coffee

Reborn Coffee, Inc. (NASDAQ: REBN) is a California-based specialty coffee retailer focused on delivering high-quality, handcrafted coffee experiences. With a growing global footprint and a dedication to innovation, Reborn is redefining the coffeehouse model through its premium products and technology-forward initiatives.

Forward-Looking Statements

All statements in this release that are not based on historical fact are “forward-looking statements.” While management has based any forward-looking statements included in this release on its current expectations, the information on which such expectations were based may change. Forward-looking statements involve inherent risks and uncertainties which could cause actual results to differ materially from those in the forward-looking statements, as a result of various factors including those risks and uncertainties described in the Risk Factors and Management’s Discussion and Analysis of Financial Condition and Results of Operations sections of our recent filings with the Securities and Exchange Commission (“SEC”) including our Form 10-K for the year ended December 31, 2025, which can be found on the SEC’s website at www.sec.gov. Such risks, uncertainties, and other factors include, but are not limited to, the Company’s ability to continue as a going concern, the Company’s ability to successfully open additional locations, the Company’s ability to expand its business both within and outside of California (including as it relates to increasing sales and growing Average Unit Volumes at our existing stores), the degree of customer loyalty to our stores and products, the fluctuation of economic conditions, competition and inflation. We urge you to consider those risks and uncertainties in evaluating our forward-looking statements. We caution readers not to place undue reliance upon any such forward-looking statements, which speak only as of the date made. The Company undertakes no obligation to update these statements for revisions or changes after the date of this release, except as required by law.

Contacts

Investor Relations Contact:
Chris Tyson
Executive Vice President
MZ North America
REBN@mzgroup.us
949-491-8235

Company Contact:
Reborn Coffee, Inc.
ir@reborncoffee.com

New York, New York, Sept. 11, 2026 (GLOBE NEWSWIRE) — Antelope Enterprise Holdings Limited (NASDAQ Capital Market: AEHL) (“Antelope Enterprise”, “AEHL” or the “Company”), which provides livestreaming ecommerce services, business management and information systems consulting services in China, today announced the pricing of a $6.0 million aggregate original principal amount convertible promissory note (the “Note”) to Stratosphere Capital Management Inc. (the “Purchaser”) pursuant to a Note Purchase Agreement entered into on September 9, 2026 (“Issuance Date”).

The Company estimates that the net proceeds from the offering of the Note will be approximately $6.0 million, after deducting estimated offering expenses payable by the Company.

The Note will bear interest at a rate of 8.00% per annum, which will accrue from the Issuance Date until the Note is paid in full, and is payable in cash. The Note has no fixed maturity date and the Note in full or in any portion is convertible into the Company’s Class A ordinary shares, no par value per share, at the option of the holder at any time on or after the Issuance Date. The conversion price will be equal to 80% of the lowest daily volume-weighted average price (VWAP) of the ordinary shares on the Nasdaq Capital Market during the three trading days ending on and including the applicable conversion date.

Conversions of the Note are subject to a strict beneficial ownership limitation, meaning the holder will not have the right to convert any portion of the Note if, immediately following such conversion, the holder and its affiliates would beneficially own in excess of 9.99% of the Company’s issued and outstanding ordinary shares. Additionally, the ordinary shares issuable upon conversion of the Note are subject to a Conversion Shares Registration Cap of 12,000,000 shares.

The Notes are being offered pursuant to a “shelf” registration statement on Form F-3 (File No. 333-295047), that was previously filed by the Company and became effective under the rules of the Securities and Exchange Commission (the “SEC”) on May 5, 2026. A preliminary prospectus supplement relating to the Offering will be filed with the SEC and will be available on the website of the SEC at www.sec.gov. Before investing in the Offering, you should read in their entirety the preliminary prospectus supplement and the accompanying prospectus and the other documents that the Company has filed with the SEC, which provide more information about the Company and the Offering.

This press release does not constitute an offer to sell or the solicitation of an offer to buy the securities, nor shall there be any sale of the securities in any state or jurisdiction in which such offer, solicitation, or sale would be unlawful prior to the registration or qualification under the securities laws of such state or jurisdiction. Any unregistered conversion shares issued in excess of the registration cap will constitute “restricted securities” under the Securities Act of 1933, as amended, and may not be offered, sold, or otherwise transferred absent an effective registration statement or an available exemption from registration.

About Antelope Enterprise Holdings Limited

Antelope Enterprise Holdings Limited (“Antelope Enterprise”, “AEHL” or the “Company”) engages holds a 51% ownership position in Hainan Kylin Cloud Services Technology Co. Ltd (“Kylin Cloud”), which operates a livestreaming e-commerce business in China. For more information, please visit our website at https://aehltd.com.

Safe Harbor Statement

Certain of the statements made in this press release are “forward-looking statements” within the meaning and protections of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements include statements with respect to our beliefs, plans, objectives, goals, expectations, anticipations, assumptions, estimates, intentions, and future performance, and involve known and unknown risks, uncertainties and other factors, which may be beyond our control, and which may cause the actual results, performance, capital, ownership or achievements of the Company to be materially different from future results, performance or achievements expressed or implied by such forward-looking statements. Forward-looking statements in this press release include, without limitation, future Bitcoin market performance and developments in the Bitcoin industry, our ability to regain customers lost resulting in a decline in our revenues, the continued stable macroeconomic environment in the PRC, the consumer and technology sectors continuing to exhibit sound long-term fundamentals, our ability to continue as a going concern, our ability to raise capital to meet our capital needs, and our ability to continue to grow our business management, information system consulting, and online social commerce and live streaming business. All statements other than statements of historical fact are statements that could be forward-looking statements. You can identify these forward-looking statements through our use of words such as “may,” “will,” “anticipate,” “assume,” “should,” “indicate,” “would,” “believe,” “contemplate,” “expect,” “estimate,” “continue,” “plan,” “point to,” “project,” “could,” “intend,” “target” and other similar words and expressions of the future.

All written or oral forward-looking statements attributable to us are expressly qualified in their entirety by this cautionary notice, including, without limitation, those risks and uncertainties described in our annual report on Form 6-K for the year ended March 31, 2026 and otherwise in our SEC reports and filings. Such reports are available upon request from the Company, or from the Securities and Exchange Commission, including through the SEC’s Internet website at http://www.sec.gov. We have no obligation and do not undertake to update, revise or correct any of the forward-looking statements after the date hereof, or after the respective dates on which any such statements otherwise are made.

Contact Information:
Antelope Enterprise Holdings Limited
Xiaoying Song, Chief Financial Officer
info@aehltd.com

WFS Investor Relations Inc.
Email: services@wfsir.com
+1 628 283 9214

NEW YORK, Sept. 11, 2026 (GLOBE NEWSWIRE) — via BioMedWire — Quantum BioPharma Ltd. (NASDAQ: QNTM) today announces its placement in an editorial published by BioMedWire (BMW), one of 75+ brands within the Dynamic Brand Portfolio@IBN (InvestorBrandNetwork), a specialized communications platform with a focus on financial news and content distribution for private and public companies and the investment community.

To view the full publication, “Historic First in MS Treatment Could Reshape a Multibillion-Dollar Therapeutics Market,” please visit: https://ibn.fm/HOCTP

Today’s multiple sclerosis (“MS”) treatments can slow down disease progression, but none of them halt it outright, and none give back the function patients have already lost. Close to a million people in the United States, and nearly 2.9 million worldwide, live with that reality, watching a condition that steadily chips away at mobility, eyesight and basic physical control.

That gap in treatment options just picked up a serious new contender. Quantum BioPharma Ltd. has received U.S. Food and Drug Administration (“FDA”) clearance to launch a phase 2 trial of Lucid-MS, a patented, first-in-class candidate designed not to calm the immune system but to shield, and potentially rebuild, the myelin sheath itself. The clearance sets up what would be the first time in history that a drug built on this exact mechanism gets tested in people living with MS, a milestone significant enough that it has already drawn a fresh buy rating from Wall Street analysts. 

About Quantum BioPharma Ltd.

Quantum is a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative and metabolic disorders and alcohol misuse disorders with drug candidates in different stages of development. Through its wholly owned subsidiary, Lucid Psycheceuticals Inc., Quantum is focused on the research and development of its lead compound, Lucid-MS. Lucid-MS is a patented new chemical entity shown to prevent and reverse myelin degradation, the underlying mechanism of multiple sclerosis, in preclinical models. Quantum invented UNBUZZD(TM) and spun out its OTC version to a company, Unbuzzd Wellness Inc. (“Unbuzzd”) (formerly Celly Nutrition Corp.), led by industry veterans. Quantum retains ownership of 19.84% (as of March 31, 2026) of Unbuzzd at www.unbuzzd.com. The agreement with Unbuzzd also includes royalty payments of 7% of sales from unbuzzd(TM) until payments to Quantum total $250 million. Once $250 million is reached, the royalty drops to 3% in perpetuity. Quantum retains 100% of the rights to develop similar products or alternative formulations specifically for pharmaceutical and medical uses.

For further information, please visit the company’s website at www.QuantumBioPharma.com.

NOTE TO INVESTORS: The latest news and updates relating to QNTM are available in the company’s newsroom at https://ibn.fm/QNTM

About BioMedWire

BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed) and Life Sciences sectors. It is one of 75+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.

BMW is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

DISCLAIMER: BioMedWire (BMW) is the source of the Article and content set forth above. References to any issuer other than the profiled issuer are intended solely to identify industry participants and do not constitute an endorsement of any issuer and do not constitute a comparison to the profiled issuer. The commentary, views and opinions expressed in this release by BMW are solely those of BMW. Readers of this Article and content agree that they cannot and will not seek to hold liable BMW for any investment decisions by their readers or subscribers. BMW is a news dissemination and financial marketing solutions provider and are NOT registered broker-dealers/analysts/investment advisers, hold no investment licenses and may NOT sell, offer to sell or offer to buy any security.

The Article and content related to the profiled company represent the personal and subjective views of the Author and are subject to change at any time without notice. The information provided in the Article and the content has been obtained from sources which the Author believes to be reliable. However, the Author has not independently verified or otherwise investigated all such information. None of the Author, BMW, or any of their respective affiliates, guarantee the accuracy or completeness of any such information. This Article and content are not, and should not be regarded as investment advice or as a recommendation regarding any particular security or course of action; readers are strongly urged to speak with their own investment advisor and review all of the profiled issuer’s filings made with the Securities and Exchange Commission before making any investment decisions and should understand the risks associated with an investment in the profiled issuer’s securities, including, but not limited to, the complete loss of your investment.

BMW HOLDS NO SHARES OF ANY COMPANY NAMED IN THIS RELEASE.

This release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. “Forward-looking statements” describe future expectations, plans, results, or strategies and are generally preceded by words such as “may”, “future”, “plan” or “planned”, “will” or “should”, “expected,” “anticipates”, “draft”, “eventually” or “projected”. You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company’s annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and BMW undertakes no obligation to update such statements.

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer

BioMedWire
Austin, Texas
www.BioMedWire.com
512.354.7000 Office
Editor@BioMedWire.com

BioMedWire is powered by IBN

  • Access the video webcast here

HOUSTON, Sept. 11, 2026 (GLOBE NEWSWIRE) — Moleculin Biotech, Inc., (Nasdaq: MBRX) (“Moleculin” or the “Company”), today announced that its pre-recorded presentation from the H.C. Wainwright 28th Annual Global Investment Conference is now available for on-demand viewing here.

The presentation, featuring Walter Klemp, Chairman and Chief Executive Officer of Moleculin, provides an overview of the Company as well as recent corporate and clinical developments.

The on-demand presentation is available for viewing beginning today, September 11, 2026, at 7:00 a.m. ET, and can be accessed through the Events page on the Investors section of the Company’s website (moleculin.com). 

Management will be available on-site at the conference being held September 14-16, 2026, in New York, NY to participate in one-on-one meetings with qualified members of the investor community who are registered to attend the conference. For more information about the conference, please visit the conference website. 

About Moleculin Biotech, Inc.

Moleculin Biotech, Inc. is a Phase 3 clinical stage pharmaceutical company advancing a pipeline of therapeutic candidates addressing hard-to-treat tumors and viruses. The Company’s lead program, Annamycin (also known as naxtarubicin), is a highly efficacious and well tolerated anthracycline designed to avoid multidrug resistance mechanisms and to lack the cardiotoxicity common with currently prescribed anthracyclines. Annamycin is currently in development for the treatment of relapsed or refractory acute myeloid leukemia (AML) and soft tissue sarcoma (STS) lung metastases.

The Company has begun the MIRACLE (Moleculin R/R AML AnnAraC Clinical Evaluation) Trial (MB-108), a pivotal, adaptive design, multi-center, randomized, double-blind, placebo-controlled Phase 2/3 trial evaluating Annamycin in combination with cytarabine, together referred to as AnnAraC (the combination of Annamycin and cytarabine, also referred to as “Ara-C”) for the treatment of relapsed or refractory acute myeloid leukemia. Following a successful Phase 1B/2 study (MB-106), with input from the FDA, the Company believes it has substantially de-risked the development pathway towards a potential approval for Annamycin for the treatment of AML. This study remains subject to appropriate future filings with potential additional feedback from the FDA and their foreign equivalents.

Additionally, the Company is developing WP1066, an Immune/Transcription Modulator capable of inhibiting p-STAT3 and other oncogenic transcription factors while also stimulating a natural immune response, targeting brain tumors, pancreatic and other cancers. Moleculin also has in its pipeline a portfolio of antimetabolites, including WP1122 for the potential treatment of pathogenic viruses, as well as certain cancer indications.

For more information about the Company, please visit www.moleculin.com and connect on X, LinkedIn and Facebook.

Forward-Looking Statements

Some of the statements in this release are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995, which involve risks and uncertainties. Forward-looking statements in this press release include, without limitation, the potential efficacy and safety of Annamycin and AnnAraC in R/R AML and the expectation that interim efficacy trends observed in a limited patient population will be confirmed in the full study population (the interim results presented are based on a small sample size (n=45), have not achieved statistical significance, and may not be predictive of results from the completed trial). Moleculin will require significant additional financing, for which the Company has no commitments, in order to conduct its clinical trials as described in this press release, and the milestones described in this press release assume the Company’s ability to secure such financing on a timely basis. Although Moleculin believes that the expectations reflected in such forward-looking statements are reasonable as of the date made, expectations may prove to have been materially different from the results expressed or implied by such forward-looking statements. The Company relies on the reports of its expert with regard to the absence of cardiotoxicity. The dataset referenced in this press release is subject to the review of the data from future subjects in its current and future clinical trials and long-term follow-up with subjects in its current trials. Moleculin has attempted to identify forward-looking statements by terminology including ‘believes,’ ‘estimates,’ ‘anticipates,’ ‘expects,’ ‘plans,’ ‘projects,’ ‘intends,’ ‘potential,’ ‘may,’ ‘could,’ ‘might,’ ‘will,’ ‘should,’ ‘approximately’ or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. These statements are only predictions and involve known and unknown risks, uncertainties, and other factors, including those discussed under Item 1A. “Risk Factors” in our most recently filed Form 10-K filed with the Securities and Exchange Commission (SEC) and updated from time to time in our Form 10-Q filings and in our other public filings with the SEC. Any forward-looking statements contained in this release speak only as of its date. We undertake no obligation to update any forward-looking statements contained in this release to reflect events or circumstances occurring after its date or to reflect the occurrence of unanticipated events.

Investor Contact:
JTC Team, LLC
Jenene Thomas
(908) 824-0775
MBRX@jtcir.com

Transaction Establishes RWB in Germany and the United Kingdom, Two of Europe’s Most Important Medical Cannabis Markets

Businesses Comprising the European Platform Dispensed or Distributed More Than Twelve Tonnes of Medical Cannabis in the Twelve Months Ended July 20261

TORONTO, Sept. 11, 2026 (GLOBE NEWSWIRE) — Red White & Bloom Brands Inc. (CSE: RWB) (“RWB” or the “Company”) is pleased to announce that it has closed a strategic transaction with HEAL Botanicals Pharma Inc. (the “Transaction”), pursuant to which RWB now holds a controlling interest in HEAL Europe Holdings Corp. (“HEH”), a newly incorporated entity established by HEAL Botanicals Pharma Inc. for purposes of the Transaction. HEH provides RWB with an integrated European medical cannabis platform comprising operations and investments in Germany, the United Kingdom and other European markets (the “European Platform”).

The Transaction represents a significant milestone in RWB’s international growth strategy and provides the Company with exposure to established businesses spanning across pharmacy operations, pharmaceutical distribution, medical cannabis brands, patient access, fulfillment and logistics. The European Platform includes the Grünhorn group of companies (“Grünhorn”), which fulfilled approximately 290,000 medical cannabis prescriptions in the twelve months ended July 2026. Collectively, the businesses comprising the European Platform dispensed or distributed over 12 tonnes of medical cannabis in the same period2.

The Transaction gives RWB a strategic foothold in two of Europe’s largest economies and key medical cannabis markets, with established operations, infrastructure, brands, patient demand and experienced teams already in place.

Significant European Market Opportunity

Germany has emerged as Europe’s largest regulated medical cannabis market, with demand accelerating following regulatory reforms introduced in 2024. Medical cannabis imports increased from approximately 73 tonnes in 2024 to approximately 205 tonnes in 20253, representing a year-over-year increase of approximately 176%. Further, industry data indicates that Germany’s pharmacy-based medical cannabis market surpassed €1 billion in annual sales in 20254.

The United Kingdom represents another significant long-term opportunity, supported by a large addressable market, importing over 30,000 kilograms of dried cannabis flower in 20255, an established private medical cannabis sector and considerable potential for continued patient adoption as awareness and access expand.

Together, entering into Germany and the United Kingdom provide RWB with a strategic foothold across two of Europe’s largest economies and key medical cannabis markets, creating opportunities to leverage established operations, brands, infrastructure and expertise as the Company builds its European Platform.

Management Commentary

“Over the past several months, we have strengthened and repositioned RWB through the strategic divesture of our Florida operations and expanded our Canadian platform through the recent acquisition of Ayurcann Inc.,” said Colby De Zen, President of RWB. “With the foundation of the Company strengthened, we are now positioned to continue executing on our broader growth strategy. Closing this transaction marks an important milestone in that strategy and establishes a meaningful platform for RWB’s expansion into Europe. Germany has rapidly emerged as Europe’s largest medical cannabis market, while the United Kingdom represents another significant and growing opportunity. Importantly, we are entering these markets with established businesses, proven operating infrastructure and experienced teams already in place. We believe this gives RWB an exceptional foundation from which to scale, expand our presence and capitalize on the significant opportunities we see across the European market.”

Grünhorn – Established German Medical Cannabis Platform

Through the Transaction, RWB acquired a controlling economic interest in Grünhorn, an established participant in Germany’s rapidly expanding medical cannabis market.

Grünhorn’s operating ecosystem encompasses online medical cannabis pharmacy operations, pharmaceutical distribution and wholesale capabilities, fulfillment and logistics infrastructure and digital patient access. These complementary capabilities provide RWB with an established platform serving patients and healthcare providers throughout the German medical cannabis market.

RWB believes Grünhorn’s established market presence, infrastructure and operating capabilities provide a strong foundation from which to participate in the continued growth and development of the German market.

United Kingdom Platform

RWB’s controlling interest in Leva HEAL Limited (“Leva”) and Zerenia Clinics Limited (“Zerenia”), which operates a private medical cannabis clinic in the United Kingdom, provide the Company with exposure to the United Kingdom’s developing private medical cannabis and healthcare market.

The United Kingdom platform complements Grünhorn’s presence in Germany and provides RWB with an additional avenue for growth as patient access, physician awareness and acceptance of medical cannabis continue to develop.

Together, the German and UK businesses provide RWB with a multi-market European platform and opportunities to share expertise, infrastructure, brands and operating capabilities across jurisdictions.

Transaction Structure and Ownership

On closing, RWB acquired approximately a 62.63% controlling interest in HEH from Heal Botanicals Pharma Inc. for nominal consideration. Through HEH’s ownership structure, RWB now holds an indirect 50.1% interest in Grünhorn Gruppe AG and its underlying operating businesses, reflecting RWB’s 62.63% acquired equity interest in HEH and HEH’s 80% equity interest in Grünhorn Gruppe AG.

RWB also acquired a direct 29.82% interest in both Zerenia and Leva with Heal Botanicals Pharma Inc. continuing to hold a 19.93% direct interest respectively. Combined with RWB’s indirect interest held through HEH, which holds 50.25% of Zerenia and Leva, RWB holds an effective interest of approximately 61.3% in each of Leva and Zerenia.

The Transaction therefore provides RWB with controlling economic interests in the principal businesses comprising the European Platform.

Senior Secured Credit Facility

In order to support the European Platform and its continued growth, RWB has committed to provide HEH with a senior secured credit facility of up to a maximum principal amount of C$25 million (the “Facility”), of which an aggregate of C$18.7 million has been advanced to date.

The principal terms of the Facility include:

  • a maximum committed principal amount of C$25 million, of which C$18.7 million has been advanced to date (C$15.7 million advanced as of June 30, 2026, with an additional C$3 million advanced on August 4, 2026);
  • interest at a fixed rate of 12% per annum;
  • interest during the first six months following closing (“the PIK Period”) will be capitalized and added to the outstanding principal;
  • a three-year term maturing September 10, 2029, with interest following the PIK Period payable from HEH’s cash flow in accordance with the terms set out in the definitive financing documents; and
  • a senior secured position over the assets of HEH, supported by guarantees and/or security from the relevant operating subsidiaries, in each case under the applicable financing and security documents.

In addition, approximately C$2.5 million of existing shareholder loans and intercompany balances will remain outstanding and be carried into HEH.

The combination of controlling equity ownership and senior secured financing provides RWB with participation in the long-term growth of the European Platform while preserving the protections and economics associated with its secured lending position.

About Red White & Bloom Brands Inc.

Red White & Bloom Brands Inc. is a publicly listed multi-jurisdictional cannabis company with operations and investments in regulated markets. The Company is focused on building and acquiring leading cannabis brands and operating assets while pursuing disciplined growth through strategic acquisitions, investments and partnerships. The Company is listed on the Canadian Securities Exchange under the symbol “RWB”.

For further information, please contact:

Edoardo Mattei, Chief Financial Officer
Red White & Bloom Brands Inc.
Email: ir@redwhitebloom.com

The Canadian Securities Exchange has neither approved nor disapproved the contents of this press release. Neither the Canadian Securities Exchange nor its Market Regulator (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this release.

Visit us on the web: https://www.redwhitebloom.com/

Follow us on social media:

X: @rwbbrands
Facebook: @redwhitebloombrands
Instagram: @redwhitebloombrands

FORWARD-LOOKING INFORMATION

Certain information contained in this news release may constitute “forward-looking information” or “forward-looking statements” within the meaning of applicable Canadian securities legislation. Forward-looking information is often identified by words such as “plans,” “expects,” “may,” “should,” “could,” “will,” “intends,” “anticipates,” “believes,” “estimates,” and “forecasts,” or variations or negative forms of such words and phrases, as well as terms such as “pro forma” and “scheduled,” and other similar expressions that refer to future events or outcomes.

Forward-looking information in this release include, without limitation, statements relating to the availability and funding of future advances under the Facility; the anticipated benefits of the Transaction; the growth and development of the German and United Kingdom medical cannabis markets; the future operations of HEH and its subsidiaries and investments; RWB’s expansion within the European medical cannabis market; potential collaboration among the businesses comprising the European Platform; RWB’s ability to fund further advances under the Facility; the recoverability of amounts advanced to HEH; and other statements that are not historical facts. Such forward-looking information involves known and unknown risks, uncertainties and other factors that may cause actual results or events to differ materially from those expressed or implied. Material risk factors include, without limitation: the risk that HEH is unable to repay amounts advanced under the Facility and that the Company is required to record an impairment or expected credit loss on its loan receivable; the Company’s own liquidity position and its ability to fund further advances, as described in the going concern disclosure in the Company’s most recent annual financial statements and management’s discussion and analysis; the risk that the guarantees and security granted in favour of the Company prove unenforceable in the relevant foreign jurisdictions; changes to German law and regulation governing telemedicine prescribing, mail-order dispensing and the importation of medical cannabis; changes to United Kingdom licensing and prescribing requirements; the fact that the majority of the HEH entities are unaudited and that historical operating metrics have not been independently verified; integration, foreign exchange, minority shareholder; shareholder loans, and governance risks; and the risk that the anticipated benefits of the Transaction are not realized.

In making the forward-looking information contained in this news release, the Company has applied a number of material factors and assumptions, including that all required consents, approvals and acceptances will be maintained; HEH and its businesses comprising the European Platform will operate substantially as anticipated; the European medical cannabis markets will continue to develop and expand; sufficient cash flow or financing will be available to satisfy obligations as they become due; the guarantees and security granted in favour of the Company will remain valid and enforceable; and there will be no material adverse change in the regulatory or business environment in the jurisdictions in which HEH and its subsidiaries carry on business.

The prescription and dispensing volumes disclosed in this news release are based on information provided by the businesses comprising the European Platform. These figures are unaudited and have not been independently verified. In presenting these figures, the Company has assumed that the underlying information is accurate and complete, that the figures are representative of ordinary-course operations and that the figures are presented on a 100% basis without adjustment for RWB’s proportionate economic interests in the applicable businesses.

Additional risks and uncertainties affecting the Company are described in the Company’s most recently filed management’s discussion and analysis and other continuous disclosure documents, available under the Company’s profile on SEDAR+ at www.sedarplus.ca. Readers are cautioned not to place undue reliance on forward-looking information. The forward-looking information contained in this news release is made as of the date of this news release, and the Company undertakes no obligation to update or revise any forward-looking statement, whether as a result of new information, future events or otherwise, except as expressly required by applicable securities laws.

____________________________________
1
Unaudited; presented on a 100% Basis; not adjusted for RWB’s economic interest post-close
2 Unaudited; presented on a 100% basis and not adjusted for RWB’s economic interest post-close
3 https://www.bfarm.de/SharedDocs/Bilder/DE/Diagramme/Bundesopiumstelle/Einfuhren_med_Cannabisblueten.jpg
4 https://cannamonitor.com/germany-imports-201-tonnes-of-medical-cannabis-in-2025/
5 https://businessofcannabis.com/uk-medical-cannabis-prescriptions-hit-1-7-million-in-2025-as-acmd-review-approaches

Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.